Suvorexant
FDA-approved product (tablet, oral), marketed as Belsomra.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBL- WHO therapeutic group
- Orexin receptor antagonists
- FDA pharmacologic class
- Orexin Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Suvorexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
NCT01293006 · start 2011-03-25
Registered record
- Registry ID
- NCT01293006
- Conditions
- Insomnia
- Interventions
- suvorexant; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-03-25
- Completion
- 2012-02-22
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsomniaInterventionsuvorexant; PlaceboPhasePhase 1Registry statusCompletedPharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
NCT01059851 · start 2010-05-24
Registered record
- Registry ID
- NCT01059851
- Conditions
- Insomnia
- Interventions
- Suvorexant
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-05-24
- Completion
- 2010-07-15
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsomniaInterventionSuvorexantPhasePhase 1Registry statusCompletedSafety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)
NCT01097616 · start 2010-05-05
Registered record
- Registry ID
- NCT01097616
- Conditions
- Primary Insomnia
- Interventions
- Suvorexant High Dose (HD); Suvorexant Low Dose (LD); Comparator: Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-05-05
- Completion
- 2011-12-07
- Enrolment
- 1,023
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary InsomniaInterventionSuvorexant High Dose (HD); Suvorexant Low Dose (LD); Comparator: PlaceboPhasePhase 3Registry statusCompletedA Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
NCT01021813 · start 2009-12-10
Registered record
- Registry ID
- NCT01021813
- Conditions
- Insomnia
- Interventions
- Suvorexant; Dose-matched Placebo to Suvorexant
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-12-10
- Completion
- 2011-08-01
- Enrolment
- 781
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInsomniaInterventionSuvorexant; Dose-matched Placebo to SuvorexantPhasePhase 3Registry statusCompletedPhase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
NCT00792298 · start 2008-11-05
Registered record
- Registry ID
- NCT00792298
- Conditions
- Primary Insomnia
- Interventions
- Suvorexant; Dose-matched Placebo to Suvorexant
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-11-05
- Completion
- 2009-12-26
- Enrolment
- 254
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPrimary InsomniaInterventionSuvorexant; Dose-matched Placebo to SuvorexantPhasePhase 2Registry statusCompleted